October 12, 2017
Friedreich’s ataxia (FA) is an inherited condition that causes progressive damage to the nervous systems and heart. There is currently no cure for FA, but gene editing using CRISPR/Cas9 is showing potential. Recently NIH-funded researchers have developed a highly versatile approach to CRISPR/Cas9-based therapies, which uses tiny particles of gold to deliver the therapy. Once the therapy arrives it can correct genetic mutations responsible for FA and other conditions.